Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts rate Emergent Biosolutions “Hold” on average: Of five analysts, three recommend buying, one recommends holding and one recommends selling. The average 12-month price target is $10.00.
• The stock opened at $4.58, near its 52-week low of $4.36 and well below its 52-week high of $14.06. Its market capitalization was approximately $235 million.
• Emergent reported quarterly EPS of $0.60, beating the consensus estimate of a $0.08 loss, while revenue of $234.3 million exceeded expectations of $177.5 million. However, the company posted a negative net margin of 22.95%, and analysts expect a full-year loss.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) has been assigned an average rating of "Hold" from the five brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $10.00.

Several research analysts have recently issued reports on EBS shares. Zacks Research upgraded shares of Emergent Biosolutions to a "hold" rating in a report on Tuesday, August 11th. UBS Group reiterated a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Emergent Biosolutions in a report on Friday, August 7th. HC Wainwright lowered their price objective on Emergent Biosolutions from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. Finally, Benchmark reaffirmed a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd.

Emergent Biosolutions Trading Up 2.1%

NYSE:EBS opened at $4.58 on Friday. The company has a market cap of $235.09 million, a PE ratio of -1.29 and a beta of 2.35. The business's 50 day moving average is $7.44 and its two-hundred day moving average is $8.52. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70. Emergent Biosolutions has a 52 week low of $4.36 and a 52 week high of $14.06.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.68. The business had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. On average, analysts predict that Emergent Biosolutions will post -4.63 EPS for the current year.

Insider Buying and Selling

In other news, SVP Paul Anthony Williams sold 3,000 shares of the company's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the sale, the senior vice president directly owned 159,098 shares in the company, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Emergent Biosolutions

Large investors have recently bought and sold shares of the business. Legal & General Group Plc bought a new position in shares of Emergent Biosolutions in the second quarter worth about $31,000. Torren Management LLC bought a new stake in shares of Emergent Biosolutions during the fourth quarter valued at approximately $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Emergent Biosolutions in the fourth quarter valued at approximately $45,000. Raymond James Financial Inc. acquired a new position in Emergent Biosolutions during the 2nd quarter worth $53,000. Finally, Farther Finance Advisors LLC lifted its holdings in Emergent Biosolutions by 361.3% during the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 4,827 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source